Short answer
Dexcom (DXCM) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026 announced.
Dexcom 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026 announced
- Investor focus: revenue, profitability, guidance and operating metrics in Exhibit 99.1
Item 8.01 · Other Events
- Board authorized up to $1.0 billion in common-stock repurchases through December 31, 2027
- Potential shareholder return and share-count reduction, but no guaranteed repurchase amount
- Flexible execution through open-market, private transactions, or Rule 10b5-1 plans
- Timing depends on market conditions, with Dexcom retaining authority to modify or discontinue the program
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1.344B, up 11% YoY, with U.S. growth 14% versus international growth 5%
- GAAP operating margin 24.3%, up 420 basis points, signaling strong operating leverage
- GAAP net income $275.1M, while diluted EPS rose to $0.72 from $0.70
- FY2026 revenue guidance raised to $5.20-$5.25B, with non-GAAP operating margin guidance approximately 24%
- New $1.0B share repurchase authorization, supported by $1.82B in cash and marketable securities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dexcom 8-K filings
Get the next DXCM 8-K as it lands
Follow DXCM for push alerts, or ask the research agent what this filing means.